Imexpharm Corporation (HOSE:IMP)

Market Cap	8.01T
Revenue (ttm)	2.42T
Net Income (ttm)	329.28B
Shares Out	154.01M
EPS (ttm)	2,138.06
PE Ratio	24.32
Forward PE	n/a
Dividend	500.00 (0.96%)
Ex-Dividend Date	Jun 9, 2025

Volume	173,221
Average Volume	140,543
Open	52,500
Previous Close	52,000
Day's Range	51,800 - 52,500
52-Week Range	36,100 - 56,500
Beta	0.72
RSI	54.62
Earnings Date	Jul 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.